BTIG Remains Bullish on DexCom, Inc. (DXCM)

DexCom, Inc. (NASDAQ:DXCM) is one of the best medical device stocks to invest in right now. BTIG cut the price target on DexCom, Inc. (NASDAQ:DXCM) to $80 from $85 on April 13 and reaffirmed a Buy rating on the shares. The rating update came as part of a broader research note on Medical Technology, with the firm updating its models to take into account CMS having announced its proposed rule for the FY27 inpatient prospective payment system. The firm told investors in a research note that this includes, among other things, preliminary commentary and decisions regarding new technology add-on payments.

Why DexCom Inc. (DXCM) Soared Last Week

DexCom, Inc. (NASDAQ:DXCM) is set to release its fiscal Q1 2026 financial results on Thursday, April 30, after market close. For reference, in its fiscal Q4 and full year 2025 results, the company reiterated its FY26 guidance and expects revenue in the $5.16 – $5.25 billion range with around 11-13% growth, non-GAAP gross profit margin of approximately 63-64%, non-GAAP operating margin of approximately 22-23%, and adjusted EBITDA margin of approximately 30-31%.

DexCom, Inc. (NASDAQ:DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems to allow real-time health management control. It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

While we acknowledge the risk and potential of DXCM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DXCM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.